治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值

doi:10.3969/j.issn.1007-3205.2021.05.005

河北医科大学学报 ›› 2021, Vol. 42 ›› Issue (5): 514-519.doi: 10.3969/j.issn.1007-3205.2021.05.005

治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值

1.河北北方学院研究生院，河北张家口 075000；2.河北省人民医院肿瘤五科，河北石家庄 050051

出版日期:2021-05-25 发布日期:2021-05-28
作者简介:李影（1991-），女，河北高碑店人，河北北方学院研究生院医学硕士研究生，从事肿瘤学诊治研究。

The prognostic value of pre-treatment systemic immune-inflammation index and fibrinogen in the prognosis of patients with non-small cell lung cancer

1.Graduate School of Hebei North University, Zhangjiakou 075000， China； 2.The Fifth Department of Oncology, Hebei General Hospital, Shijiazhuang 050051， China

Online:2021-05-25 Published:2021-05-28

摘要/Abstract

摘要： 目的探讨治疗前系统免疫-炎症指数（system immune-inflammation index，SII）、纤维蛋白原（fibrinogen，FIB）对非小细胞肺癌患者预后的评估价值。
方法收集经病理确诊的非小细胞肺癌患者84例的临床资料，通过受试者工作特征（receiver operating characteristic，ROC）曲线计算治疗前SII和FIB的最佳截断值作为依据。
结果治疗前SII的AUC为0.748，最佳截断值为743.384，敏感度为57.1%，特异度为90.5%；治疗前FIB的AUC为0.812，最佳截断值为3.070 g/L，敏感度为85.7%，特异度为64.3%。SII＞743.384组和SII≤743.384组NSCLC患者肿瘤分化程度较低、TNM分期晚、KPS评分低、体重减轻率差异有统计学意义（P＜0.05）。FIB＞3.070 g/L组和FIB≤3.070 g/L组NSCLC患者年龄、KPS评分、体重减轻差异有统计学意义（P＜0.01）。SII≤743.384组和SII＞743.384组的中位生存时间分别为34个月和10个月，差异有统计学意义(P＜0.001)。FIB≤3.070 g/L组未到中位生存期，FIB＞3.070 g/L组的中位生存时间为14个月,差异有统计学意义(P＜0.01)。联合检测SII与FIB，2个指标均升高组的生存期短于1个指标升高组和2个指标均不高组，差异有统计学意义（P＜0.01）。Cox回归模型进行分析，结果显示，体重减轻、治疗前FIB是NSCLC预后的危险因素(P＜0.05)。Spearman相关分析结果提示，SII和FIB有微弱的正相关关系（P＜0.05）。
结论治疗前SII和FIB与NSCLC关系密切,SII和FIB升高提示预后不良。

关键词: 癌, 非小细胞肺, 系统免疫-炎症指数, 纤维蛋白原

Abstract: Objective To evaluate the prognostic value of pre-treatment system immune-inflammation index(SII) and fibrinogen(FIB) in patients with non-small cell lung cancer(NSCLC).
Methods The clinical data of patients with pathologically diagnosed NSCLC were collected, and receiver operating characteristic(ROC) curve was used to calculate the optimal cut-off value of pre-treatment SII and FIB as the basis.
Results The area under the ROC curve(AUC) of pre-treatment SII was 0.748, and the optimal cut-off value was 743.384; the sensitivity and specificity were 57.1% and 90.5% respectively. The AUC of pre-treatment FIB was 0.812, and the optimal cut-off value was 3.070 g/L;the sensitivity and specificity were 85.7% and 64.3% respectively. NSCLC patients in SII>743.384 group and SII≤743.384 group had lower tumor differentiation, late TNM staging, lower KPS score, and different weight loss rate, and there was significant difference(P＜0.05). There were statistically significant differences in age, KPS score, and weight loss of NSCLC patients between the FIB>3.070 g/L group and the FIB≤3.070 g/L group(P＜0.01). The median survival time of SII≤743.384 group and SII＞743.384 group was 34 months and 10 months, respectively, and the difference was statistically significant(P＜0.001). The median survival time was shorter in the FIB≤3.070 g/L group, and was 14 months in the FIB>3.070 g/L group, and the difference was statistically significant(P＜0.01). Combined detection of SII and FIB indicated that the survival time of the group with two indexes increased was shorter than that with one index increased and that without an increase in the two indexes, and the difference was statistically significant(P＜0.01). Cox multivariate analysis showed that weight loss and pre-treatment fibrinogen level were independent risk factors for the prognosis of NSCLC patients(P＜0.05).The results of Spearman correlation analysis suggested that there was a weak positive correlation between SII and FIB(P＜0.05).
Conclusion Pretreated SII and FIB are closely related to NSCLC, and the increase of SII and FIB indicates poor prognosis.

Key words: carcinoma, non-small-cell lung, system immune-inflammation index, fibrinogen

李影, 刘苗苗, 何严璐琦, 张洪珍. 治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值[J]. 河北医科大学学报, 2021, 42(5): 514-519.

LI Ying, LIU Miao-miao, HE Yan-lu-qi, ZHANG Hong-zhen. The prognostic value of pre-treatment systemic immune-inflammation index and fibrinogen in the prognosis of patients with non-small cell lung cancer[J]. Journal of Hebei Medical University, 2021, 42(5): 514-519.

[1]	王天云, 奎翔, 赵春梅, 王燕. QTRT1表达与肾透明细胞癌预后及肿瘤免疫的相关性[J]. 河北医科大学学报, 2023, 44(9): 998-1005.
[2]	苏凤芹, 苏慧, 吴慧炜, 邢淑华. 花姜酮通过免疫原性死亡影响黏液表皮样癌的机制研究 [J]. 河北医科大学学报, 2023, 44(7): 767-772.
[3]	颜晰, 张金艳, 郭秀娟. 2种全自动免疫检测系统鳞状细胞癌抗原结果的一致性评价[J]. 河北医科大学学报, 2023, 44(6): 719-723,728.
[4]	张明文, 朱佳斌(综述), 张晓峰(审校). 外泌体在肿瘤诊疗中的研究进展 [J]. 河北医科大学学报, 2023, 44(6): 740-744,封三.
[5]	赖盛联, 毛敏, 黄林. CEACAM6、miR-146b、S100A6在甲状腺癌中的表达及意义分析 [J]. 河北医科大学学报, 2023, 44(5): 531-535,552.
[6]	赵乐, 吴忱思, 张瑞星, 郭占军. HBV影响甲磺酸阿帕替尼治疗肝细胞癌效果的机制研究 [J]. 河北医科大学学报, 2023, 44(4): 382-385,416.
[7]	刘尧, 靳晶, 孙雪梅, 刘畅, 焦文鹏. SOX2在食管小细胞癌中的表达及预后价值 [J]. 河北医科大学学报, 2023, 44(4): 397-401,封三.
[8]	梁新科, 王鹏飞, 霍胜男, 李建英, 侯庆田. 基于生物信息学分析LncRNA AC005479.2在甲状腺乳头状癌中的表达及相关分析 [J]. 河北医科大学学报, 2023, 44(2): 161-166.
[9]	姚平, 阮萍, 刘莹, 郑玲, 林国彪. 大导管型及小导管型肝内胆管癌的临床病理特征及预后分析 [J]. 河北医科大学学报, 2023, 44(2): 218-223.
[10]	汤涛, 陈曦, 陈铜兵, 王辉. 数字PCR技术检测肺腺癌循环肿瘤DNA中EGFR突变的临床意义 [J]. 河北医科大学学报, 2023, 44(2): 224-229.
[11]	张珂欣（综述）, 刘健（审校）. PD-L1与肿瘤相关免疫细胞的表达在口腔鳞状细胞癌发生发展中的作用[J]. 河北医科大学学报, 2023, 44(10): 1237-1240,封三.
[12]	郭丽宁, 常蕊, 杨杰, 李惠. lncRNA OVAAL、miR-335、TRIM 14在子宫内膜癌中表达及与临床特征相关性研究 [J]. 河北医科大学学报, 2023, 44(1): 68-73,111.
[13]	刘尧, 靳晶, 孙雪梅, 刘静, 王肖肖, 刘月平. LAG-3及肿瘤浸润淋巴细胞在食管鳞状细胞癌患者预后中的作用 [J]. 河北医科大学学报, 2022, 43(9): 1014-1019,1024.
[14]	杜若昕, 郭欣燕（综述）, 张伟, 芦希艳（审校）. 肝细胞癌中索拉非尼耐药性机制的研究进展[J]. 河北医科大学学报, 2022, 43(9): 1091-1095.
[15]	张尧雨, 杨淑琳（综述）, 魏林, 宋小天（审校）. 外泌体在肝癌耐药中的研究进展 [J]. 河北医科大学学报, 2022, 43(8): 966-970.

治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值

The prognostic value of pre-treatment systemic immune-inflammation index and fibrinogen in the prognosis of patients with non-small cell lung cancer

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价